David R Bakal1, Lara E Coelho2, Paula M Luz2, Jesse L Clark1, Raquel B De Boni2, Sandra W Cardoso2, Valdilea G Veloso2, Jordan E Lake1,3, Beatriz Grinsztejn2. 1. Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Le Conte Ave, Los Angeles, CA 90095, USA. 2. Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil, Manguinhos, Rio de Janeiro, Brazil. 3. Department of Medicine, The University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin St., Houston, TX, USA.
Abstract
Background: Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear. Objectives: In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine obesity rates before and after ART initiation and to analyse risk factors for obesity on ART. Methods: We retrospectively analysed data from individuals initiating ART between 2000 and 2015. BMI was calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had ≥90 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox regression models. Results: Of participants analysed at baseline (n = 1794), 61.3% were male, 48.3% were white and 7.9% were obese. Among participants followed longitudinally (n = 1567), 66.2% primarily used an NNRTI, 32.9% a PI and 0.9% an integrase strand transfer inhibitor (INSTI); 18.3% developed obesity and obesity incidence was 37.4 per 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of an INSTI as the primary ART core drug (adjusted HR 7.12, P < 0.0001); other risk factors included younger age, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, hypertension and diabetes mellitus. Conclusions: Obesity following ART initiation is frequent among HIV-infected adults. Key risk factors include female sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and the development of obesity is needed.
Background: Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear. Objectives: In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine obesity rates before and after ART initiation and to analyse risk factors for obesity on ART. Methods: We retrospectively analysed data from individuals initiating ART between 2000 and 2015. BMI was calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had ≥90 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox regression models. Results: Of participants analysed at baseline (n = 1794), 61.3% were male, 48.3% were white and 7.9% were obese. Among participants followed longitudinally (n = 1567), 66.2% primarily used an NNRTI, 32.9% a PI and 0.9% an integrase strand transfer inhibitor (INSTI); 18.3% developed obesity and obesity incidence was 37.4 per 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of an INSTI as the primary ART core drug (adjusted HR 7.12, P < 0.0001); other risk factors included younger age, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, hypertension and diabetes mellitus. Conclusions: Obesity following ART initiation is frequent among HIV-infected adults. Key risk factors include female sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and the development of obesity is needed.
Authors: Jamison Norwood; Megan Turner; Carmen Bofill; Peter Rebeiro; Bryan Shepherd; Sally Bebawy; Todd Hulgan; Stephen Raffanti; David W Haas; Timothy R Sterling; John R Koethe Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Beatriz Grinsztejn; Valdilea G Veloso; Ruth K Friedman; Ronaldo I Moreira; Paula M Luz; Dayse P Campos; José H Pilotto; Sandra W Cardoso; Jeanne C Keruly; Richard D Moore Journal: AIDS Date: 2009-10-23 Impact factor: 4.177
Authors: Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown Journal: Clin Infect Dis Date: 2016-01-20 Impact factor: 9.079
Authors: Thiago S Torres; Paula M Luz; Monica Derrico; Luciane Velasque; Eduarda Grinsztejn; Valdiléa G Veloso; Sandra W Cardoso; Marília Santini-Oliveira; Beatriz Grinsztejn; Raquel Brandini De Boni Journal: PLoS One Date: 2014-12-23 Impact factor: 3.240
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Paula Debroy; Jordan E Lake; Carlee Moser; Maxine Olefsky; Kristine M Erlandson; Ann Scherzinger; James H Stein; Judith S Currier; Todd T Brown; Grace A McComsey Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079
Authors: Raphael J Landovitz; Sahar Z Zangeneh; Gordon Chau; Beatriz Grinsztejn; Joseph J Eron; Halima Dawood; Manya Magnus; Albert Y Liu; Ravindre Panchia; Mina C Hosseinipour; Ryan Kofron; David A Margolis; Alex Rinehart; Adeola Adeyeye; David Burns; Marybeth McCauley; Myron S Cohen; Judith S Currier Journal: Clin Infect Dis Date: 2020-01-02 Impact factor: 9.079
Authors: Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey Journal: Clin Gastroenterol Hepatol Date: 2020-10-16 Impact factor: 11.382
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546
Authors: Maj David A Kline; Colton Daniels; Xiaohe Xu; Thankam Sunil; Anuradha Ganesan; Brian K Agan; Rhonda E Colombo; Karl C Kronmann; Jason M Blaylock; Jason F Okulicz; A Elizabeth Markelz Journal: Mil Med Date: 2021-02-26 Impact factor: 1.437
Authors: Bruno Emond; Carmine Rossi; Aurélie Côté-Sergent; Keith Dunn; Patrick Lefebvre; Marie-Hélène Lafeuille; Prina Donga Journal: J Health Econ Outcomes Res Date: 2021-06-14